Skye Bioscience, Inc. (SKYE)
1.775
-0.18
(-8.97%)
USD |
NASDAQ |
Aug 28, 16:00
1.83
+0.06
(+3.10%)
Pre-Market: 09:02
Skye Bioscience Cash from Operations (Quarterly) : -7.122M for June 30, 2026
Cash from Operations (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -7.122M |
| March 31, 2026 | -8.558M |
| December 31, 2025 | -9.766M |
| September 30, 2025 | -13.36M |
| June 30, 2025 | -10.75M |
| March 31, 2025 | -9.186M |
| December 31, 2024 | -8.173M |
| September 30, 2024 | -5.263M |
| June 30, 2024 | -7.094M |
| March 31, 2024 | -4.708M |
| December 31, 2023 | -3.845M |
| September 30, 2023 | -4.055M |
| June 30, 2023 | -1.992M |
| March 31, 2023 | -4.061M |
| December 31, 2022 | -4.872M |
| September 30, 2022 | -2.057M |
| June 30, 2022 | -2.901M |
| March 31, 2022 | -2.915M |
| December 31, 2021 | -1.969M |
| September 30, 2021 | -1.486M |
| June 30, 2021 | -1.671M |
| March 31, 2021 | -1.348M |
| December 31, 2020 | -1.786M |
| September 30, 2020 | -1.974M |
| June 30, 2020 | -1.028M |
| Date | Value |
|---|---|
| March 31, 2020 | -1.266M |
| December 31, 2019 | -1.503M |
| September 30, 2019 | -1.488M |
| June 30, 2019 | -1.605M |
| March 31, 2019 | -1.431M |
| December 31, 2018 | -1.014M |
| September 30, 2018 | -0.8163M |
| June 30, 2018 | -1.059M |
| March 31, 2018 | -1.053M |
| December 31, 2017 | -2.144M |
| September 30, 2017 | -0.10M |
| June 30, 2017 | -0.2714M |
| March 31, 2017 | -0.8164M |
| December 31, 2016 | -0.6628M |
| September 30, 2016 | -0.5117M |
| June 30, 2016 | -1.23M |
| March 31, 2016 | -1.148M |
| December 31, 2015 | -1.076M |
| September 30, 2015 | -1.295M |
| June 30, 2015 | -0.5677M |
| March 31, 2015 | -0.7517M |
| December 31, 2014 | -0.8026M |
| September 30, 2014 | -0.9517M |
| April 30, 2014 | 0.0033M |
| January 31, 2014 | -0.0041M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| Regeneron Pharmaceuticals, Inc. | 813.00M |
| Viking Therapeutics, Inc. | -125.17M |
| ACADIA Pharmaceuticals, Inc. | 100.78M |
| Alnylam Pharmaceuticals, Inc. | 326.72M |
| Anika Therapeutics, Inc. | -0.684M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | 7.142M |
| Cash from Financing (Quarterly) | -0.101M |
| Free Cash Flow | -38.81M |
| Free Cash Flow Per Share (Quarterly) | -1.435 |
| Free Cash Flow to Equity (Quarterly) | -6.989M |
| Free Cash Flow to Firm (Quarterly) | -7.118M |
| Free Cash Flow Yield | -440.8% |